TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 45 years of age, inclusive, at screening and in good general health based on medical history, physical examination, and laboratory evaluation;~* If female, must be (as documented by patient reported medical history):~* postmenopausal (at least 1 year without spontaneous menses), or~* surgically sterile (tubal ligation or hysterectomy), or~* using acceptable contraception \[e.g., sexual partner with non-reversed vasectomy (with azoospermia in 2 tests), 2 barrier methods (e.g., condom, diaphragm, or spermicide), or intra-uterine device\];~* Body mass index (BMI) between 18 and 32 kg/m2, inclusive;~* Able to swallow the assigned study medication tablet whole; and,~* Able to fulfill the requirements of the protocol and provide written informed consent.~Exclusion Criteria:~* History or presence of any condition or gastrointestinal (GI) surgery causing malabsorption or an effect on GI motility;~* Any uncontrolled acute disease or major surgical operation requiring hospitalization within 1 month of screening;~* History of diabetes, syncope, cardiovascular, hepatic, or renal disease;~* Uncontrolled chronic diseases such as hypertension, systemic lupus erythematosus, or rheumatoid arthritis;~* History of cancer within the last 5 years (except for basal cell carcinoma with a documented 6-month remission);~* Any known enzyme-inducer, enzyme-inhibitor, or reported chronic exposure to enzyme-inducers such as paint solvents or pesticides within 30 days of treatment;~* Any prescription drug or herbal remedy within 14 days prior to scheduled dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Asacol 6x400 mg Q24h at 7 am for 7 days
- 2 (Type: EXPERIMENTAL): Asacol 2x400 mg Q8h at 7 am, 3 pm, and 11 pm for 7 days
- 3 (Type: EXPERIMENTAL): Lialda 2x1.2g Q24h at 7 am for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All primary hyperparathyroidism patients eligible for parathyroidectomy (PTx). Both bilateral and focused mode of PTx will be considered for this study, based on the surgeon's preference.~* Re-operative primary hyperparathyroidism patients who have undergone a failed prior PTx.~Exclusion Criteria:~* Patients with concurrent parathyroid and thyroid disease that require total thyroidectomy.~* Patients with secondary or tertiary hyperparathyroidism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- NIRAF Detection Technology + (Type: EXPERIMENTAL): Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo parathyroidectomy (PTx).
- NIRAF Detection Technology - (Type: NO_INTERVENTION): Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo parathyroidectomy (PTx).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inactivated Poliomyelitis Vaccine Made From Sabin Strain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants of 2 months of age~* The legal identity certificate (birth/household register) and vaccination certificate of the participants can be provided, and the legal guardian can provide the legal identity certificate (identity card).~* Guardians are able to understand the experimental vaccine, volunteer to participate in the study and sign informed consent for participation.~* Guardians are capable of using thermometer, graduated scale, filling diary card and contact card.~* Participants are not vaccinated with polio vaccine and immunoglobulin (except for Hepatitis b specific immunoglobulin) after birth, no vaccination of live vaccine within 28 days before enrollment and no vaccination of inactivated vaccine within 14 days before enrollment.~* Participants or guardians are able to obey and follow all study instructions, complete all the monitoring, and cooperate to complete collection of blood sample.~* Axillary temperature ≤37℃~Exclusion Criteria:~* Allergic to any active substance, inactive substance or materials used during production such as kanamycin.~* Patients with fever or acute disease.~* Have thrombocytopenia or hemorrhagic diseases~* Patients undergoing immunosuppressive therapy or immunodeficiency~* Have uncontrolled epilepsy or other progressive neurological disorders~* Other situations that the investigator consider as non-eligible

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 3 Months
- Healthy Volunteers: t

Study Arms:
- Inactivated Poliomyelitis Vaccine Made From Sabin Strain (Type: EXPERIMENTAL): Primary 3-dose of sIPV and booster 1 dose of sIPV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Fasting triglycerides 500-1500 mg/dl~* Not on other lipid altering therapy, OR on stable lipid altering therapy~Main Exclusion Criteria:~* Type I diabetes or uncontrolled type II diabetes~* Recent cardiovascular or coronary event~* History of pancreatitis~* History or evidence of major and clinically significant diseases that would interfere with the conduct of the study or interpretation of data~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- PRC-4016 (Type: EXPERIMENTAL): PRC-4016, oral administration once daily, capsule
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral administration once daily, capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male~* aged 50 years or older~* diagnostic claim for BPH~* prescription claim for an AB and a 5ARI in the observation period (5ARI must occur within a 6-month window after the AB).~* continuously eligible for 6 months prior to and 12 months after index prescription date~Exclusion Criteria:~* prostate or bladder cancer during the study period~* any prostate-related surgical procedure within 5 months of the index prescription date~* prescription claim for finasteride 1 mg for male pattern baldness during the study period~* 5ARI therapy prior to initiation of AB therapy

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early initiation of 5ARI therapy (Type: None): Patients starting 5ARI therapy within 30 days of initiating AB therapy
- Delayed initiation of 5ARI therapy (Type: None): Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Sabin-IPV Replacement Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects aged from 60 days to 89 days old at the date of recruitment;~* with informed consent signed by parent(s) or guardians;~* parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions;~* subjects did not receive any vaccines within 14 days;~* axillary temperature ≤37.0℃~Exclusion Criteria:~* allergic to any ingredient of vaccine or with allergy history to any vaccine;~* acute febrile disease or infectious disease;~* serious chronic diseases;~* any other factor that makes the investigator determines the subject is unsuitable for this study;

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- group 1 (Type: EXPERIMENTAL): 180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV
- group 2 (Type: ACTIVE_COMPARATOR): 180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* women consulting for vaginal discharge~* local resident~* willingness and ability to consent~Exclusion Criteria:~* sex worker consulting for active screening~* main complaint of lower abdominal pain~* allergy to one of the study drugs

- Gender: FEMALE
- Minimum Age: 11 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients aged 18 to 50 years~* Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen seasons~* Positive SPT and specific IgE values of at least Class 2 for grass pollen allergens~* A score of greater than or equal to 12 out of a possible 18 on the Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS)~Exclusion Criteria:~* Patients with symptoms of rhinoconjunctivitis during the grass pollen season due to sensitisation to allergens other than grass pollen must not be included. Patients must be asymptomatic to all other allergens during the grass pollen season. Patients who have allergic rhinitis due to perennial allergen may not be included.~* Asthma requiring treatment other than beta-2 inhaled agonists.~* Patients who have received any desensitisation treatment for grass pollen or with any other allergen within the previous 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 300 IR (4M) (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
- 300 IR (2M) (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Staccato: A Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CD4 lymphocyte count above 350/microliter and viral HIV1-RNA below 50 copies/ml on antiretroviral treatment.~Exclusion Criteria:~* Virologic failure of treatment. Failure of treatment defined as a treatment switch motivated by high viral loads on treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of the Next Generation Intraocular Lens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum 22 years of age~* Bilateral cataracts for which posterior chamber IOL implantation has been planned~* Corneal astigmatism:~* Normal corneal topography~* Availability, willingness and sufficient cognitive awareness to comply with examination procedures and study visits~* Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries~* Ability to understand and respond to a questionnaire in English~Exclusion Criteria:~* Irregular corneal astigmatism~* Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)~* Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery, Including prophylactic peripheral iridotomies and peripheral laser retinal repairs~* Poorly-controlled diabetes~* Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes~* Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial~* Desire for monovision correction

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Investigational Device: Next Generation TECNIS IOL (Type: EXPERIMENTAL): Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
- Control Device: TECNIS Monofocal IOL (Type: ACTIVE_COMPARATOR): Control Monofocal Intraocular Lens: TECNIS Monofocal IOL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Investigator determined diagnosis of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria with symptomatology from childhood to adulthood, symptoms present before age seven years and continue to meet full DSM-IV criteria at time of assessment~* Diagnosis confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) at Baseline and Adult ADHD Investigator Symptom Rating Scale (AISRS) score of 24 or greater as determined by the Investigator at Baseline~* Global Assessment of Functioning (GAF) Scale score of 41 to 60, inclusive, at Baseline~* Minimum weight of 100 lbs (45.4 kg) at Screening~* Negative urine drug test at the Screening and Baseline Visits when tested for drugs of abuse~Exclusion Criteria:~* Known to be non-responders to methylphenidate or other stimulants for the treatment of ADHD~* History of allergy, sensitivity or contraindication to methylphenidate or components of methylphenidate HCL extended-release tablets~* Coexisting medical condition or taking concomitant medication that would interfere with safe administration of methylphenidate in the Investigator's opinion~* Known structural cardiac abnormality~* Diagnosis of or family history of Tourette's syndrome, or motor or verbal tics~* history of seizures or a seizure disorder other than febrile seizures in childhood~* Glaucoma~* Uncontrolled hyperthyroidism or hypothyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of BST104 (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons who was diagnosed with functional indigestion in adult over 19 years of age and did not require early medication was conducted with the participation~Exclusion Criteria:~* Persons who is allergic to natural substances and substances~* Persons who need treatment for reflux esophagitis, gastric ulcer, and acute gastritis according to gastroscopy findings~* Persons with past history of stomach or esophagus surgery, or patients who are unable to take esophagogastroduodenoscopy~* Persons who continue to apply medications that can cause ulcers such as steroids, nonsteroidal anti-inflammatory drugs and aspirin (Patients taking low-dose aspirin for prevention of cardiovascular disease were allowed)~* Persons diagnosed with malignant tumors within five years~* Persons who drink more than four times a week~* Severe liver failure (more than 2 .5 times the normal upper limit of ALT, AST, γGT)~* In case of a severe renal failure, including chronic or acute kidney failure~* Persons with uncontrolled diabetes, cerebrovascular disease,~* Persons diagnosed with diseases requiring surgery within three months~* Zollinger Ellison sy n drome, esophageal stenosis, duodenal ulcer, pancreatitis, absorption disorder, or malignant disease in the gastrointestinal tract~* Pregnant women, nursing mothers, having plans for pregnancy~* In case of participating another human study within four weeks

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Treatment group (Type: ACTIVE_COMPARATOR): The randomly assigned target was given a Lonicera Flos extract (BST104) 175 mg/day for eight weeks.
- Placebo group (Type: PLACEBO_COMPARATOR): The randomly assigned target was given a placebo for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIV Translating Initiatives for Depression Into Effective Solutions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. current 9-item Patient Health Questionnaire (PHQ-9) score of 10 or more and~2. current treatment in the HIV clinic.~Exclusion Criteria:~1. patients who do not have access to a telephone,~2. patients with current suicidal ideation,~3. patients with significant cognitive impairment as indicated by a score \< 10 on the HIV Dementia Scale, and~4. patients with a chart diagnosis of schizophrenia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Collaborative Care Intervention (Type: EXPERIMENTAL): HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.
- Arm 2: Usual Care (Type: NO_INTERVENTION): HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete